CO2022003608A2 - Cianopirrolidinas sustituidas con actividad como inhibidores de usp30 - Google Patents

Cianopirrolidinas sustituidas con actividad como inhibidores de usp30

Info

Publication number
CO2022003608A2
CO2022003608A2 CONC2022/0003608A CO2022003608A CO2022003608A2 CO 2022003608 A2 CO2022003608 A2 CO 2022003608A2 CO 2022003608 A CO2022003608 A CO 2022003608A CO 2022003608 A2 CO2022003608 A2 CO 2022003608A2
Authority
CO
Colombia
Prior art keywords
activity
inhibitors
cyanopyrrolidines
substituted
usp30
Prior art date
Application number
CONC2022/0003608A
Other languages
English (en)
Inventor
Paul William Thompson
Christopher Andrew Luckhurst
Mark Ian Kemp
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of CO2022003608A2 publication Critical patent/CO2022003608A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una clase de cianopirrolidinas sustituidas con actividad como inhibidores de la enzima de desubiquitinación USP30, que tiene utilidad en una variedad de áreas terapéuticas, incluyendo condiciones que involucran la disfunción mitocondrial, cáncer y fibrosis: (I).
CONC2022/0003608A 2019-09-04 2022-03-25 Cianopirrolidinas sustituidas con actividad como inhibidores de usp30 CO2022003608A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1912674.7A GB201912674D0 (en) 2019-09-04 2019-09-04 Novel compounds
PCT/EP2020/074540 WO2021043870A1 (en) 2019-09-04 2020-09-03 Substituted cyanopyrrolidines with activity as usp30 inhibitors

Publications (1)

Publication Number Publication Date
CO2022003608A2 true CO2022003608A2 (es) 2022-04-19

Family

ID=68207049

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0003608A CO2022003608A2 (es) 2019-09-04 2022-03-25 Cianopirrolidinas sustituidas con actividad como inhibidores de usp30

Country Status (14)

Country Link
US (1) US20220315572A1 (es)
EP (1) EP4025573B1 (es)
JP (1) JP2022546717A (es)
KR (1) KR20220054867A (es)
CN (1) CN114341133B (es)
AU (1) AU2020340527A1 (es)
BR (1) BR112022003527A2 (es)
CA (1) CA3146040A1 (es)
CO (1) CO2022003608A2 (es)
GB (1) GB201912674D0 (es)
IL (1) IL290929A (es)
MX (1) MX2022002686A (es)
WO (1) WO2021043870A1 (es)
ZA (1) ZA202203775B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112513036B (zh) 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
AU2019356011A1 (en) 2018-10-05 2021-04-01 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
CA3171349A1 (en) 2020-04-08 2021-10-14 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
BR112022020644A2 (pt) 2020-05-28 2022-12-06 Mission Therapeutics Ltd Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial
JP2023529570A (ja) 2020-06-04 2023-07-11 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン
CN115836073B (zh) 2020-06-08 2024-08-27 特殊治疗有限公司 用于治疗线粒体功能障碍、癌症和纤维化的作为usp30抑制剂的1-(5-(2-氰基吡啶-4-基)噁唑-2-羰基)-4-甲基六氢吡咯并[3,4-b]吡咯-5(1h)-甲腈
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
EP4441044A1 (en) 2021-12-01 2024-10-09 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
KR20240132148A (ko) * 2023-02-24 2024-09-03 연세대학교 산학협력단 인덴 유도체를 유효성분으로 포함하는 섬유화의 예방 또는 치료용 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
AU2001256981A1 (en) 2000-04-06 2001-10-23 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007119214A2 (en) 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
EP2152079A4 (en) 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
PE20090606A1 (es) 2007-08-20 2009-06-17 Glaxo Group Ltd Nuevos inhibidores de catepsina c y uso
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
PE20091843A1 (es) 2008-04-18 2010-01-07 Glaxo Group Ltd Inhibidores de catepsina c
PE20091888A1 (es) 2008-04-18 2010-01-17 Glaxo Group Ltd Inhibidores de catepsina c
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
US9738648B2 (en) 2013-07-31 2017-08-22 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
US9963444B2 (en) 2014-05-19 2018-05-08 Northeastern University N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
EP3148572A4 (en) 2014-05-27 2017-12-27 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
CN112707893B (zh) 2015-03-30 2023-10-31 特殊治疗有限公司 作为usp30抑制剂的1-氰基吡咯烷化合物
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
MA43753A (fr) * 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
JP6959332B2 (ja) 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
WO2018213150A1 (en) 2017-05-15 2018-11-22 Mitobridge, Inc. Usp30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
EA202090871A1 (ru) * 2017-10-06 2020-07-03 Форма Терапьютикс, Инк. Ингибирование убиквитин-специфической пептидазы 30
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
CN112513036B (zh) 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
JP7434285B2 (ja) 2018-08-14 2024-02-20 アムジエン・インコーポレーテツド Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用
AU2019356011A1 (en) 2018-10-05 2021-04-01 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
BR112022020644A2 (pt) * 2020-05-28 2022-12-06 Mission Therapeutics Ltd Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial

Also Published As

Publication number Publication date
CN114341133A (zh) 2022-04-12
BR112022003527A2 (pt) 2022-05-17
GB201912674D0 (en) 2019-10-16
EP4025573A1 (en) 2022-07-13
US20220315572A1 (en) 2022-10-06
AU2020340527A1 (en) 2022-04-21
JP2022546717A (ja) 2022-11-07
CN114341133B (zh) 2024-02-27
KR20220054867A (ko) 2022-05-03
EP4025573B1 (en) 2024-07-24
IL290929A (en) 2022-04-01
CA3146040A1 (en) 2021-03-11
ZA202203775B (en) 2024-01-31
WO2021043870A1 (en) 2021-03-11
MX2022002686A (es) 2022-04-07

Similar Documents

Publication Publication Date Title
CO2022003608A2 (es) Cianopirrolidinas sustituidas con actividad como inhibidores de usp30
CO2022014134A2 (es) N-cianopirrolidinas con actividad como inhibidores de usp30
CO2019014682A2 (es) Composiciones y métodos para enzimas de internalización
ECSP17055491A (es) Ácidos 3-alquil-4-amido-bicíclico [4,5,0] hidroxámico como inhibidores de hdac
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
CO2018006714A2 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
CO2017007694A2 (es) Composiciones de bacillus licheniformis rti184 para beneficiar el crecimiento de plantas
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201890079A1 (ru) Клеточная система для направленной доставки активного ингредиента
CL2017002427A1 (es) Producción de ácido ribonucleico libre de células.
WO2015019198A3 (en) High potency pancreatin pharmaceutical compositions
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
UY4759S (es) Modelo industrial de cuerpo de extintor de incendios
MX2016000480A (es) Composiciones farmaceuticas de pancreatina de alta potencia.
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
BR112018069506A2 (pt) métodos para transfectar plantas e para reduzir eventos de integração aleatória
AR113270A1 (es) Compuesto de heteroarilo con contenido de nitrógeno y su uso farmacéutico
CO2022017233A2 (es) 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis
UY37534A (es) Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda
CO2022017112A2 (es) N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
CO2017011046A2 (es) Prenda absorbente con buen ajuste
CL2019000429A1 (es) Conjugado de minoxidil y peptidos.
ES2514140A1 (es) Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento